April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Snapshot Test for Investigating Gels of Anti-Glaucoma Compounds as Topical Formulations
Author Affiliations & Notes
  • P.-P. Elena
    Iris Pharma, La Gaude, France
  • C. Pollin
    Iris Pharma, La Gaude, France
  • F. Bermon
    Iris Pharma, La Gaude, France
  • T. Amar
    Iris Pharma, La Gaude, France
  • T. Caillaud
    Iris Pharma, La Gaude, France
  • H. Polzer
    MEDproject Pharma, Oberhaching, Germany
  • Footnotes
    Commercial Relationships  P.-P. Elena, Iris Pharma, France, E; C. Pollin, Iris Pharma, France, E; F. Bermon, Iris Pharma, France, E; T. Amar, Iris Pharma, France, E; T. Caillaud, Iris Pharma, France, E; H. Polzer, MEDproject Pharma, E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 6002. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P.-P. Elena, C. Pollin, F. Bermon, T. Amar, T. Caillaud, H. Polzer; Snapshot Test for Investigating Gels of Anti-Glaucoma Compounds as Topical Formulations. Invest. Ophthalmol. Vis. Sci. 2009;50(13):6002.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To get predictive data on the ocular penetration of several compounds formulated as mucoadhesive polymer fluid gels in a time-sharing, money-saving test.

Methods: : A single topical application of several 0.1% and 0.2% brimonidine tartrate formulations (mixture with various mixed polymers MP formulations: carbomer, polyvinylalcohol, povidone, etc...) into both eyes of pigmented rabbits, was compared to Alphagan® P 0.1%, Alphagan® P 0.15%, and Alphagan® 0.2%. The aqueous humor was sampled 15min, 30min, 40min, 60min, 120min, and 240min after treatment, and brimonidine content was evaluated by HPLC-MS.

Results: : Compared to Alphagan®, both the area under the curve (AUC15-240min) ratios and the Cmax ratios (at 40min) were within a same range, as shown in the following table:Formulation Cmax ratio vs Alphagan® AUC15-240min ratio vs Alphagan®Alphagan® 0.2% 1.00 1.00Alphagan® P 0.15% 0.64 0.95Alphagan® P 0.1% 0.73 0.82MP 701-04509-01 0.1% 1.05 0.88MP 701-04509 0.2% 1.58 2.33MP 730-0450901 0.2% 2.05 1.75MP 700-04509 0.2% 1.59 1.83Similar experiments were performed using 0.1%-timolol/2%-dorzolamide formulations vs Cosopt® and showed similar results.

Keywords: drug toxicity/drug effects • intraocular pressure 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.